 The development of mesenchymal stem cells as cell-based drug delivery vectors for numerous clinical indications, including cancer, has significant promise. However, the limited tumor tropism and broad biodistribution observed using conventional MSc raises concerns for toxicity to non-target peripheral tissues. This article was authored by Timothy G Kruger, Daniel L J Forek, Samuel Ardenmead and others.